RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Xynomic Pharmaceuticals Holdings Stock

Xynomic Pharmaceuticals Holdings ROE 2024

Xynomic Pharmaceuticals Holdings ROE

0

Ticker

XYNO

ISIN

US98421X1028

In 2024, Xynomic Pharmaceuticals Holdings's return on equity (ROE) was 0, a 0% increase from the 0 ROE in the previous year.

Xynomic Pharmaceuticals Holdings Aktienanalyse

What does Xynomic Pharmaceuticals Holdings do?

Xynomic Pharmaceuticals Holdings Inc is a biopharmaceutical company based in New York City that focuses on the development and marketing of innovative cancer therapies. The company was founded in 2016 and has since become a leading player in the industry. In this post, we would like to tell you more about the history and business model of Xynomic Pharmaceuticals, as well as the various products that the company offers. History of Xynomic Pharmaceuticals Holdings Inc Xynomic Pharmaceuticals was founded in 2016 by an experienced team of pharmaceutical industry experts, including Dr. Peng Wang, the CEO of the company. The company's goal from the beginning was to develop and bring to market innovative cancer drugs to help patients around the world. The company has made significant progress since its inception and now has an impressive portfolio of cancer therapies. Business model of Xynomic Pharmaceuticals The business model of Xynomic Pharmaceuticals is focused on developing high-quality cancer therapies and bringing them to market. The company works closely with leading academic institutions and commercial partners to identify and explore innovative concepts for combating cancer. Xynomic Pharmaceuticals' products are designed to treat specific types of cancer and be tailored to the needs of patients worldwide. Products of Xynomic Pharmaceuticals Xynomic Pharmaceuticals' portfolio includes a variety of innovative cancer therapies tailored to different types of cancer. One example is the drug Abexinostat, which is currently in phase 3 clinical trials and is used to treat peripheral T-cell lymphoma (PTCL). Abexinostat is an oral medication that targets epigenetic enzymes involved in the development of cancer. The drug has the potential to extend the survival of patients with PTCL and is a promising new treatment option for this serious disease. Another product of Xynomic Pharmaceuticals is the drug XP-102, which is used to treat fatty liver diseases. Fatty liver disease, also known as non-alcoholic fatty liver disease (NAFLD), is a common condition that occurs due to factors such as obesity and diabetes. XP-102 has the potential to improve liver performance and treat this disease, which currently has no effective medical treatment. Conclusion Xynomic Pharmaceuticals Holdings Inc is a rising biopharmaceutical company that develops innovative cancer drugs. The company has made significant progress since its inception and has an impressive portfolio of cancer therapies. Xynomic Pharmaceuticals works closely with leading partners and academic institutions to develop and provide innovative cancer therapies. The company's products have the potential to change the lives of patients worldwide and offer new treatment options for serious diseases. Xynomic Pharmaceuticals Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Xynomic Pharmaceuticals Holdings's Return on Equity (ROE)

Xynomic Pharmaceuticals Holdings's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Xynomic Pharmaceuticals Holdings's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Xynomic Pharmaceuticals Holdings's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Xynomic Pharmaceuticals Holdings’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Xynomic Pharmaceuticals Holdings stock

What is the ROE (Return on Equity) of Xynomic Pharmaceuticals Holdings this year?

The ROE of Xynomic Pharmaceuticals Holdings this year is 0 undefined.

How has the Return on Equity (ROE) of Xynomic Pharmaceuticals Holdings developed compared to the previous year?

The ROE of Xynomic Pharmaceuticals Holdings has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Xynomic Pharmaceuticals Holdings?

A high ROE indicates that Xynomic Pharmaceuticals Holdings generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Xynomic Pharmaceuticals Holdings?

A low ROE can indicate that Xynomic Pharmaceuticals Holdings is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Xynomic Pharmaceuticals Holdings affect the company?

A change in ROE (Return on Equity) of Xynomic Pharmaceuticals Holdings can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Xynomic Pharmaceuticals Holdings?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Xynomic Pharmaceuticals Holdings?

Some factors that can influence Xynomic Pharmaceuticals Holdings's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Xynomic Pharmaceuticals Holdings pay?

Over the past 12 months, Xynomic Pharmaceuticals Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xynomic Pharmaceuticals Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Xynomic Pharmaceuticals Holdings?

The current dividend yield of Xynomic Pharmaceuticals Holdings is .

When does Xynomic Pharmaceuticals Holdings pay dividends?

Xynomic Pharmaceuticals Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Xynomic Pharmaceuticals Holdings?

Xynomic Pharmaceuticals Holdings paid dividends every year for the past 0 years.

What is the dividend of Xynomic Pharmaceuticals Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Xynomic Pharmaceuticals Holdings located?

Xynomic Pharmaceuticals Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Xynomic Pharmaceuticals Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Xynomic Pharmaceuticals Holdings from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Xynomic Pharmaceuticals Holdings pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Xynomic Pharmaceuticals Holdings in the year 2023?

In the year 2023, Xynomic Pharmaceuticals Holdings distributed 0 USD as dividends.

In which currency does Xynomic Pharmaceuticals Holdings pay out the dividend?

The dividends of Xynomic Pharmaceuticals Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Xynomic Pharmaceuticals Holdings

Our stock analysis for Xynomic Pharmaceuticals Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Xynomic Pharmaceuticals Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.